Bevacizumab, as an anti-VEGF monoclonal antibody, may inhibit the formation of arteriovenous malformation in the epidermis and brain, and affects the progress of blood malformation vessels. The gene discussed is VEGFA; the disease is arteriovenous hemangioma/malformation.